Harvard Bioscience Inc (HBIO)

Harvard Bioscience insiders who bought shares in the last year have seen a 15% increase in their investment, adding US$4.1 million to the company's market value. The largest insider purchase was made by Independent Director William Snider for US$104,000 at a price below the current market value. While there have been no insider sales, the article suggests that higher insider ownership would provide more confidence, and no recent transactions have occurred in the last three months.

Insiders at Harvard Bioscience (NASDAQ:HBIO) who bought shares in the past year have seen significant returns, with the stock climbing 15% and adding US$4.1 million to the company's market value. Their original US$202.4k investment is now worth US$290.3k. Although the biggest insider purchase was at a lower price point, the overall insider buying activity suggests confidence in the company, though the article also notes the desire for higher insider ownership.

Insiders at Harvard Bioscience (NASDAQ:HBIO) who purchased shares in the last year have seen a positive return on their investment, with the stock climbing 15% and adding US$4.1 million to the company's market value. Their original US$202.4k purchase is now worth US$290.3k. While there have been no insider transactions in the last three months, the buying activity over the past year, particularly a US$104k purchase by Independent Director William Snider, suggests a degree of insider confidence, although insider ownership remains at 7.1%.

Harvard Bioscience (HBIO) reported an 11% revenue growth in Q2 2026, driven by strong demand from CRO customers and new product platforms, leading to a raised full-year revenue guidance to 3-5%. Despite top-line success, a product and geographic mix shift towards lower-margin segments, including cellular and molecular technology (CMT) and China sales, caused a revision in the full-year adjusted gross margin outlook to 57-59%. The company is executing "Project Viking" for manufacturing consolidation, expected to yield significant cost savings from 2027, and is focusing on expanding high-margin recurring revenue streams and localized manufacturing in China for long-term profitability.

Benchmark has increased its price target for Harvard Bioscience Inc. (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating, following the company's strong second-quarter revenue of $22.7 million which surpassed guidance. The company also raised its full-year 2026 revenue growth guidance to 3%-5%. Despite this, analysts expect the company to not be profitable in fiscal 2026.